A team of Goodwin Procter attorneys recently advised the underwriters in the Argos Therapeutics, Inc. initial public offering. The underwriting syndicate was led by Piper Jaffray & Co., Stifel, Nicolaus & Company and JMP Securities LLC. Needham & Company, LLC acted as co-manager.
Shares of Argos Therapeutics priced at $8.00 per share and began trading on the NASDAQ Global Market on February 7, 2014 under the symbol “ARGS.” The offering initially sold 5,625,000 shares of common stock, and, on February 28, 2014, the underwriters purchased an additional 603,725 shares pursuant to the overallotment option granted to them by the company.
Argos Therapeutics, co-founded by Nobel Prize winner Dr. Ralph Steinman, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. The company is based in Durham, N.C.
The Goodwin team advising the underwriters included associate Courtney Hetrick. Partner Duncan Greenhalgh and senior attorney Crystal Komm (IP) provided additional support.
Read the Argos press release announcing the offering for more information.